Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.
Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Recently,
clinical trials have focused on novel antiangiogenic agents in combination with chemotherapy
or alone in women with primary and recurrent ovarian cancer. Antiangiogenic agents
include monoclonal antibodies, tyrosine-kinase inhibitors, and peptibodies. Many of
these agents, including bevacizumab, pazopanib, nintedanib, cediranib, and trebananib,
have been evaluated in randomized Phase III clinical trials, and all have demonstrated
a progression-free survival (PFS) benefit. Specifically, maintenance pazopanib was
shown to improve PFS in women with newly diagnosed EOC. Pazopanib, an oral TKI, inhibits
several kinase receptors, including those for vascular endothelial growth factor (-1,-2,-3),
platelet-derived growth factor (-α and -β), and fibroblast growth factor. It also
targets stem cell-factor receptor (c-kit), interleukin 2-inducible T-cell kinase,
lymphocyte-specific protein tyrosine kinase, and colony-stimulating factor 1 receptor.
Pazopanib has been investigated in several Phase II and III clinical trials, with
results indicating a potential role in the management of EOC. This article provides
an overview of pazopanib in the treatment of EOC.
Type
Journal articlePermalink
https://hdl.handle.net/10161/15735Published Version (Please cite this version)
10.2147/IJWH.S49781Publication Info
Davidson, Brittany A; & Secord, Angeles Alvarez (2014). Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.
Int J Womens Health, 6. pp. 289-300. 10.2147/IJWH.S49781. Retrieved from https://hdl.handle.net/10161/15735.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Brittany A Davidson
Associate Professor of Obstetrics and Gynecology
Angeles Alvarez Secord
Professor of Obstetrics and Gynecology
My primary research interest has focused on on novel therapeutics, biomarkers and
clinical trial development for ovarian and endometrial cancer. My fundamental goal
is to develop a strong translational research program at Duke University in the Gynecologic
Oncology Division, where knowledge we glean from our basic science research can be
incorporated into our clinical trial program. Specifically, my focus is on biologic
therapy and molecular biomarkers to direct therapy in patients with ovari
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info